There should be a significant effect on turnover, but API has signaled as I understand it a similar reduction in discount terms to that when Pfizer left therefore should maintain net profit all other things being equal.
But there wasn't much fat to play with so I do not think any if them are in a position to handle a wholesaler specific problem.
API could be more at risk as sole distributor of Alphapharm products which as one if the main supplier of generics would have one of the major impacts of the PBS reform, particularly has having mature products.
Pfizer has done a good job (for them) of maintaining the supply of the Lipitor molecule..
- Forums
- ASX - By Stock
- API
- what are peoples thoughts here
what are peoples thoughts here, page-16
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add API (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online